Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer

Drugs

Volumn 68, Issue 8, 2008, Pages 1105-1113

  Carlson, Josh J ^a   Veenstra, David L ^a,b   Ramsey, Scott D ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Carboplatin, therapeutic use; Cisplatin, therapeutic use; Non small cell lung cancer, treatment; Pharmacoeconomics

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; TENIPOSIDE; VINBLASTINE; VINDESINE;

BIOSIS; CANCER STAGING; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; EMBASE; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MEDLINE; MONOTHERAPY; PRACTICE GUIDELINE; REVIEW; SYSTEMATIC REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE;

EID: 43749111105     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868080-00007     Document Type: Review

References (35)

1. World Health Organization. Revised global burden of disease (GBD) 2002 estimates. Available from URL: http://www.who.int/healthinfo/bodgbd2002revised/ en/index.html [Accessed 2007 May 9]
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74-108
3. American Cancer Society. Cancer facts and figures 2007. Atlanta (GA): American Cancer Society, 2007
4. Kutikova L, Bowman L, Chang S, et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 2005; 50 (2): 143-54
5. The National Institute for Health and Clinical Excellence. ERG report: erlotinib for the treatment of relapsed non-small cell lung cancer. Liverpool: The National Institute for Health and Clinical Excellence, 2006
6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer V.2.2006 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf [Accessed 2008 Mar 19]
7. Ramsey SD, Howlader N, Etzioni RD, et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results - Medicare. J Clin Oncol 2004; 22 (24): 4971-8
8. Mather D, Sullivan SD, Parasuraman TV. Beyond survival: economic analyses of chemotherapy in advanced, inoperable NSCLC. Oncology (Williston Park) 1998; 12 (2): 199-209; discussion 210, 215-6
9. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
10. Chiou CF, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Medical Care 2003; 41 (1): 32-44
11. Ng R, Hasan B, Mittmann N, et al. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer. A report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25 (16): 2256-61
12. Dooms CA, Lievens YN, Vansteenkiste JF. Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur Respir J 2006; 27 (5): 895-901
13. Pimentel FL, Bhalla S, Laranjeira L, et al. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer. Lung Cancer 2006; 52 (3): 365-71
14. Neymark N, Lianes P, Smit EF, et al. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. Pharmacoeconomics 2005; 23 (11): 1155-66
15. Novello S, Kielhorn A, Stynes G, et al. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/ carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer 2005; 48 (3): 379-87
16. Holmes J, Dunlop D, Hemmett L, et al. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer. Pharmacoeconomics 2004; 22 (9): 581-9
17. Billingham LJ, Bathers S, Burton A, et al. Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2002; 37 (2): 219-25
18. Clegg A, Scott DA, Hewitson P, et al. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax 2002; 57 (1): 20-8
19. Lees M, Aristides M, Maniadakis N, et al. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics 2002; 20 (5): 325-37
20. Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002; 20 (5): 1344-52
21. Ramsey SD, Moinpour CM, Lovato LC, et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 2002; 94 (4): 291-7
22. Rubio-Terres C, Tisaire JL, Kobina S, et al. Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer. Lung Cancer 2002; 35 (1): 81-9
23. Annemans L, Giaccone G, Vergnenegre A. The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. Anticancer Drugs 1999; 10 (6): 605-15
24. Khan ZM, Rascati KL, Koeller JM. Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer. Pharmacoeconomics 1999; 16 (1): 43-57
25. Sacristan JA, Kennedy-Martin T, Rosell R, et al. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell Sciences, lung cancer. Lung Cancer 2000; 28 (2): 97-107
26. Earle CC, Evans WK. Cost-effectiveness of paclitaxel plus USA. cisplatin in advanced non-small-cell lung cancer. Br J Cancer 1999; 80 (5-6): 815-20
27. Evans WK. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC. Oncology (Williston Park) 1998; 12 (3 Suppl. 4): 18-25; discussion 25-6
28. Tennvall GR, Fernberg JO. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer. Med Oncol 1998; 15 (2): 129-36
29. Evans WK, Will BP, Berthelot JM, et al. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol 1997; 15 (9): 3038-48
30. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13 (10): 716-7
31. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18 (10): 2095-103
32. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353 (2): 123-32
33. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22 (19): 3852-9
34. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99 (11): 847-57
35. Gold M, Seigel J, Russell L, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996